Takeda Pharmaceutical Company Limited

Request correction

Corporate brand

Unclaimed

Japanese multinational pharmaceutical company focused on innovative medicines and vaccines.

Last updated October 14, 2026

AI crawler reads

No AI crawler has read this profile since Oct 28, 2026.

Overview

Takeda Pharmaceutical Company Limited is a Japanese multinational pharmaceutical company headquartered in Osaka. Its origins date to 1781, when Chobei Takeda began selling traditional Japanese and Chinese medicines in Osaka. The business was incorporated as a company in 1925 and gradually developed from a domestic medicine distributor into a research-based pharmaceutical enterprise with operations across major global markets. Takeda's modern identity was shaped by international expansion, licensing, biotechnology partnerships, and a series of major acquisitions. Its 1977 joint venture with Abbott Laboratories, TAP Pharmaceuticals, established an important foothold in the United States and contributed to the commercialization of Lupron and Prevacid. The company later acquired specialist research and commercial businesses, including Syrrx, Millennium Pharmaceuticals, Nycomed, Ariad Pharmaceuticals, TiGenix, and ultimately Shire. The Shire transaction, completed in 2019 for more than US$50 billion, substantially enlarged Takeda's global scale, strengthened its presence in rare diseases and gastrointestinal medicine, and made it one of the world's largest pharmaceutical companies by revenue. Takeda's principal research and commercial areas are gastroenterology, rare diseases, oncology, neuroscience, plasma-derived therapies, and vaccines. Its portfolio has included products such as Actos, Velcade, Ninlaro, Entyvio, Takhzyro, Adcetris, and Eohilia, although product ownership and marketing rights have changed through licensing, acquisitions, and divestitures. The company has also maintained research collaborations in areas including RNA interference, artificial intelligence, immunology, cell therapy, and antibody-based therapeutics. The company has pursued a portfolio-shaping strategy since the Shire acquisition. It sold or transferred a number of non-core consumer, respiratory, ophthalmology, and regional pharmaceutical assets to companies including AstraZeneca, Novartis, Acino, Stada, Orifarm, Celltrion, and Corza Health. These transactions were intended to concentrate capital and management attention on Takeda's core growth platforms rather than on maintaining a broad consumer-health and mature-products portfolio. Takeda is listed in Japan and operates internationally through research, manufacturing, clinical development, regulatory, and commercial organizations. Christophe Weber became president and chief executive officer in 2015 and led the company through the Shire acquisition and subsequent integration. Takeda has also faced legal and reputational challenges, including the 2001 TAP Pharmaceuticals settlement involving alleged unlawful marketing of Lupron and litigation concerning the diabetes medicine pioglitazone. Its current corporate positioning emphasizes science-led innovation, specialty medicines, patient access, and a focused global portfolio.

History

Takeda traces its origins to 1781, when Chobei Takeda I established a medicine-selling business in Osaka’s Doshomachi district. The early enterprise operated within Japan’s traditional medicine trade and was initially associated with the distribution of Japanese and Chinese medicinal products. Over time, the Takeda family business expanded its commercial organization and adopted modern pharmaceutical manufacturing and research methods as Japan’s healthcare system developed. During the late nineteenth and early twentieth centuries, Takeda moved from medicine merchandising toward industrial pharmaceutical production. The company incorporated as Takeda Pharmaceutical Company in the early twentieth century and progressively built domestic manufacturing, sales and research capabilities. Its later expansion into vitamins, over-the-counter products and prescription medicines gave the company a broad presence in Japan. The Alinamin brand became particularly well known in the Japanese consumer market, although the company’s long-term strategic direction increasingly favored prescription pharmaceuticals. After the Second World War, Takeda developed into one of Japan’s largest pharmaceutical companies. The company expanded its scientific infrastructure, entered overseas markets and built a portfolio spanning metabolic disease, gastroenterology, oncology, neuroscience and other fields. A major commercial success was Actos, a diabetes medicine introduced internationally in the late 1990s. The product demonstrated the potential of Takeda’s research organization but also exposed the company to the concentration risk and eventual revenue pressure associated with patent expiry. The company accelerated internationalization through acquisitions. In 2008, Takeda acquired Millennium Pharmaceuticals, a United States biotechnology company known for oncology research and the multiple-myeloma medicine Velcade. The transaction strengthened Takeda’s position in oncology and broadened its North American research and commercial presence. In 2017, Takeda acquired Ariad Pharmaceuticals, adding oncology assets including Iclusig and reinforcing its effort to build a global specialty-medicines portfolio. The largest transformation occurred with Shire. Takeda made its agreement to acquire Shire public in 2018 after a series of proposals and negotiations. The transaction was valued at approximately £46 billion at announcement and was completed in January 2019 after shareholder and regulatory processes. Shire brought major rare-disease, gastrointestinal, neuroscience and plasma-derived therapy businesses, as well as a strong North American and European footprint. The acquisition made Takeda a substantially larger global pharmaceutical company and reduced its historic dependence on Japan. The Shire transaction also placed substantial demands on integration, financing and portfolio management. Takeda assumed significant debt and acquired a large collection of businesses and facilities. Management pursued cost synergies, operational integration and the disposal of non-core assets, including consumer-health and other businesses, to strengthen the balance sheet and concentrate resources on the company’s core therapeutic areas. External commentary has continued to debate the price paid, the pace of return on invested capital and whether the strategic benefits fully offset the transaction’s financial burden. In the 2020s, Takeda continued to emphasize specialty and innovative medicines, including gastroenterology, rare diseases, plasma-derived therapies, oncology and neuroscience, while maintaining a vaccine business. Its corporate identity also became more explicitly global. The 240th-anniversary communications launched in 2021 presented Takeda-ism, patient commitment, innovation, integrity, diversity and sustainability as elements of a single corporate purpose. Subsequent films and transit, digital and print campaigns illustrated research, manufacturing, supply, regional healthcare, climate action and collaboration. Today Takeda is a publicly traded, multinational biopharmaceutical company with Japanese roots and global operations. Its history is therefore best understood not simply as the story of a long-lived Japanese medicine company, but as a continuing transformation from a domestic family enterprise into a global specialty-pharmaceutical group shaped by research investment, cross-border acquisitions, divestitures and a patient-focused corporate brand.

2021
240th-anniversary corporate branding launched
[9]240th-anniversary corporate branding launchediyakutsushinsha.com
Takeda began a global corporate campaign centered on innovation, integrity and service to the world.
2019
Shire acquisition completed
[3]Takeda completes acquisition of Shiretakeda.com
Takeda completed the acquisition on January 8, creating a significantly larger global biopharmaceutical company.
2018
Agreement to acquire Shire announced
[4]Reuters: Takeda agrees to acquire Shirereuters.com
Takeda agreed to acquire Shire in a proposed transaction valued at approximately £46 billion at announcement.
2017
Ariad Pharmaceuticals acquired
[8]Ariad Pharmaceuticals acquiredtakeda.com
The acquisition strengthened Takeda’s oncology portfolio and added Ariad’s specialty cancer medicines and research capabilities.
2008
Millennium Pharmaceuticals acquired
[2]Takeda company historytakeda.com
Takeda acquired Millennium Pharmaceuticals, expanding its oncology research and international biotechnology capabilities.
1781
Medicine business founded in Osaka
[2]Takeda company historytakeda.com
Chobei Takeda I began selling Japanese and Chinese medicines in Osaka’s Doshomachi pharmaceutical district.

Products and positioning

A global, innovation-led prescription biopharmaceutical company focused on complex and specialty-care medicines, especially gastrointestinal disease, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines.

Gastroenterology biologic · 2014
Entyvio
Entyvio is a biologic medicine used for specified inflammatory bowel diseases, including ulcerative colitis and Crohn’s disease. It is one of Takeda’s most important gastrointestinal products and reflects the company’s focus on specialty medicines for chronic, immune-mediated conditions.
Rare-disease biologic · 2018
Takhzyro
Takhzyro is a preventive treatment for hereditary angioedema. It came into Takeda’s portfolio through the Shire acquisition and illustrates the company’s emphasis on rare diseases and specialized biologic therapies.
Oncology medicine · 2015
Ninlaro
Ninlaro is an oral proteasome inhibitor used in specified multiple-myeloma treatment settings. It is part of Takeda’s oncology portfolio and is designed for use in combination regimens under applicable prescribing information.
Neuroscience medicine · 2007
Vyvanse
Vyvanse is a lisdexamfetamine-based prescription medicine used for attention-deficit/hyperactivity disorder and, in the United States, moderate-to-severe binge-eating disorder. The brand entered Takeda’s portfolio through Shire.
Oncology medicine · 2012
Iclusig
Iclusig is a targeted cancer medicine associated with Takeda’s oncology business following the acquisition of Ariad Pharmaceuticals. It is used for specified leukemia indications and is prescribed under jurisdiction-specific labeling and safety requirements.
Plasma-derived therapy
Gammagard
Gammagard is a plasma-derived immunoglobulin product used in specified immune-deficiency and immune-mediated conditions. Plasma-derived therapies became a major strategic component of Takeda’s portfolio through Shire.

Controversies

2015
Takeda agrees to settle most pioglitazone bladder-cancer claims
Takeda agreed to establish a settlement valued at approximately US$2.37 billion for claims alleging that pioglitazone was associated with bladder cancer. The company did not admit liability in the settlement.
Source
2014
Pioglitazone bladder-cancer litigation
A federal jury awarded punitive damages in a case alleging that Takeda concealed risks associated with its diabetes medicine pioglitazone. The initial award was later reduced, and Takeda subsequently agreed to a broad settlement covering most related claims.
Source
2001
TAP Pharmaceuticals Lupron marketing case
TAP Pharmaceuticals, the Takeda-Abbott joint venture, faced civil and criminal allegations concerning the marketing of Lupron and Medicare fraud. The case resulted in an approximately US$875 million settlement with U.S. authorities.
Source

2024Nanda? transit and owned-media campaign
Japan
Beginning in January 2024, Takeda used 42 transit-advertising messages in Tokyo and Osaka built around the audience-oriented question “What is Takeda?” The messages used factual visuals and QR codes to guide audiences to explanatory owned content.
Outcome. The campaign sought to make a complex pharmaceutical business easier to understand and to improve employee engagement around the company’s work.
Source
2024Corporate film series: Climate change
Japan
The fifth film in the corporate series addressed climate change and described environmental action connected with pharmaceutical manufacturing and global health.
Outcome. The campaign broadened Takeda’s corporate-purpose communication from medicine and healthcare to the relationship between planetary and human health.
Source
2023Corporate film series: Regional healthcare
Japan
A film showed the company’s interest in regional healthcare and depicted drone-assisted medicine delivery to remote islands.
Outcome. It extended the campaign from laboratory science to access, logistics and local healthcare collaboration.
Source
2022Corporate film series: Diversity
Japan · United States
A second film focused on diversity and collaboration between teams in Japan and Boston working toward drug discovery.
Outcome. The execution connected diversity and international teamwork with innovation and recruitment-oriented corporate reputation.
Source
2022Corporate film series: Manufacturing and supply
Japan
A film set at Takeda’s Osaka manufacturing facility highlighted employees, production operations and the challenge of reliably supplying medicines.
Outcome. The campaign brought manufacturing and supply-chain work into Takeda’s public corporate narrative.
Source
2021Serve the World. Takeda. Innovatively. With Integrity.
Japan · Global
Takeda launched a corporate-branding campaign around its 240th anniversary. Advertising and an owned-media platform presented research, manufacturing, diversity and inclusion, environmental work, governance and collaboration as expressions of the company’s purpose and Takeda-ism.
Outcome. The campaign became the company’s continuing corporate-reputation platform and was extended through later television, digital, print and outdoor executions.
Source
2021Corporate film series: iPS cells
Japan
The first reported film in the series used iPS-cell research to communicate Takeda’s response to difficult medical problems and its research-led identity.
Outcome. It established the recurring format of employee-centered films tied to a broad human challenge.
Source

Brand decisions

2018
Agreement to acquire ShireM&A
Background
Takeda sought greater scale and stronger positions in rare diseases, gastroenterology, neuroscience, oncology and plasma-derived therapies while facing pressure from market competition, patent cycles and the limits of relying on domestic growth.
Action taken
The company agreed to acquire Shire for approximately £46 billion, using a combination of cash and Takeda shares. The transaction required shareholder and regulatory approvals and was completed in January 2019.
Aftermath
The deal materially expanded Takeda’s global scale and specialty portfolio but also increased leverage and integration complexity. Takeda later pursued asset sales, cost reductions and operational consolidation to reduce debt and sharpen its focus.
Announced transaction value. Approximately £46 billion (2018 announcement)
- Shire — Shire’s board recommended that shareholders support the agreed transaction after negotiations and revised proposals.
Source
2017
Acquisition of Ariad PharmaceuticalsM&A
Background
Takeda wanted to reinforce oncology and obtain additional targeted cancer medicines and research capabilities.
Action taken
Takeda acquired Ariad Pharmaceuticals in a transaction reported at approximately $5.2 billion.
Aftermath
The acquisition added Iclusig and strengthened Takeda’s oncology platform before the later Shire transaction.
Source

Recent events

Unconfirmed
Reported2026.10.27
Takeda launches Orzeyful[14]武田推出 Orzeyfulasia.nikkei.com
Takeda Pharmaceutical has fully launched Orzeyful, a narcolepsy treatment that targets the root cause rather than addressing only symptoms.
2021.04.13
Reported2021.04.14
United Airlines announces Eco-Skies Alliance sustainable fuel plan[15]美联航宣布Eco-Skies Alliance可持续航空燃料计划engadget.com
United Airlines said it had partnered with global firms in an Eco-Skies Alliance to finance the use this year of about 3.4 million gallons of low-carbon sustainable aviation fuel derived from trash.
2021.03.30
Reported2021.03.30
BridGene and Takeda announce research collaboration[16]BridGene 与武田宣布研究合作prnewswire.com
BridGene Biosciences announced a strategic research collaboration and licensing agreement with Takeda to establish up to five drug discovery programs. BridGene is eligible for potential milestone payments and royalties, while Takeda may receive exclusive licenses for selected validated targets.
2021.03.19
Reported2021.03.19
Anima Biotech and Takeda announce drug-discovery collaboration[17]Anima Biotech与武田宣布药物发现合作pharmaceutical-business-review.com
Anima Biotech announced a strategic collaboration with Takeda to discover and develop medicines for genetically defined neurological diseases. Takeda holds exclusive rights to develop and commercialise the molecules, and the parties will collaborate to advance them.
2021.01.26
Reported2021.01.26
PatientsLikeMe and Takeda announce strategic partnership[18]PatientsLikeMe与武田宣布建立战略合作关系finanznachrichten.de
PatientsLikeMe announced a strategic partnership with Takeda to enhance its digital platform and gather insights on patient experience and unmet needs, initially focusing on rare diseases, immunology, neuroscience and mental health, and gastroenterology.
2020.09.09
Reported2020.09.09
Presage and Takeda announce expanded research collaboration[19]Presage与武田宣布扩大研究合作prnewswire.com
Presage Biosciences announced a new research collaboration with Takeda to use CIVO in Phase 0 trials evaluating multiple investigational oncology agents and combinations.
Unconfirmed
Reported2019.10.23
Takeda signs exclusive global license for TAK-101[20]武田签署TAK-101全球独家许可协议pharmaceutical-business-review.com
Takeda signed a deal with COUR Pharmaceutical Development for an exclusive global license to develop and commercialize TAK-101, with COUR eligible for future payments and royalties on sales of commercialized products.

Sources20 sources

Cite this profile: Cite the canonical profile. /brand-wiki/武田製薬 · Editorial policy · How profiles are compiled